Juno Therapeutics, Inc.
JUNO
JUNO was delisted on the 5th of March, 2018.
120 hedge funds and large institutions have $2.96B invested in Juno Therapeutics, Inc. in 2015 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 34 increasing their positions, 30 reducing their positions, and 26 closing their positions.
73% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 26
24% more capital invested
Capital invested by funds: $2.39B → $2.96B (+$564M)
19% more funds holding
Funds holding: 101 → 120 (+19)
13% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 30
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
40% less call options, than puts
Call options by funds: $10.2M | Put options by funds: $16.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$62.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$57.9M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$40.6M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$33.6M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$19.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$26.7M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$16.8M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$14.9M |
| 4 |
DM
Deerfield Management
New York
|
-$8.49M |
| 5 |
Morgan Stanley
New York
|
-$7.22M |
JUNO Hedge Fund Activity: Q1 2015 in Review
120 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q1 2015, worth a combined $2.96B — up 24% from $2.39B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new JUNO positions and 26 closed out — a net gain of 19 holders — while 34 added to existing stakes and 30 trimmed.
The largest buyer was Vanguard Group, adding an estimated $62.3M. The largest seller was Ameriprise, cutting an estimated $26.7M.
- 120 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q1 2015, up from 101 in Q4 2014.
- Funds reported $2.96B of Juno Therapeutics, Inc. stock for Q1 2015, up 24% quarter-over-quarter.
- 45 funds opened new Juno Therapeutics, Inc. positions in Q1 2015 and 26 closed out, a net change of +19 holders.
- The largest Juno Therapeutics, Inc. buyer in Q1 2015 was Vanguard Group, an estimated $62.3M added.
- The largest Juno Therapeutics, Inc. seller in Q1 2015 was Ameriprise, an estimated $26.7M sold.
Based on aggregated 13F filings for Q1 2015.